OCEANIC-AF and the inferior efficacy of asundexian compared to apixaban in patients at high risk with atrial fibrillation: Have we come to the end of the road for factor XIa inhibitors?
Keith C. Ferdinand,
Asaad Nakhle
Affiliations
Keith C. Ferdinand
Corresponding author at: 1430 Tulane Ave, Mail Code 8048, New Orleans, LA 70112, United States of America.; Tulane University School of Medicine, Section of Cardiology, 1430 Tulane Ave, New Orleans, LA 70112, United States of America
Asaad Nakhle
Tulane University School of Medicine, Section of Cardiology, 1430 Tulane Ave, New Orleans, LA 70112, United States of America
